ImmunityBio

ImmunityBio's ANKTIVA achieved a 71% complete response rate in a 100-patient BCG-unresponsive NMIBC CIS trial, with responses lasting up to 54 months. The company plans to submit updated data to the EMA in Q4 2024.

ImmunityBio reports Q3 2024 financials: ANKTIVA receives J-code, coverage secured for 200M lives, net product revenue $6M, shelf life extended to 3 years, UK and EU MAA submissions planned. Net loss $85.7M, cash and marketable securities $130.4M.

NK cell therapy, a promising cancer treatment, sees robust R&D with 140+ companies developing 160+ therapies. Key players include Amgen, Innate Pharma, Nektar Therapeutics, and others. Promising therapies like Bemarituzumab, Monalizumab, and NKTR-225 are in various clinical phases. Recent milestones include Immunitybio's CAR-NK cell therapy for NHL, Nkarta's NKX019 for AAV, and KGen Biotech's SNK01 advancing to Phase II.

Vir Biotechnology reported a Q3 loss of $1.56 per share, missing estimates by -62.50%, with revenues of $2.38 million, down 72.54% from estimates. The stock has underperformed the market, down 24.5% YTD, while the Zacks Rank #3 suggests it will perform in line with the market.

ImmunityBio's stock surged 56% to $6.57 on the launch of its Phase 1 trial for CD19 t-haNK cell therapy in South Africa, aiming to enroll up to 100 patients by early 2025. The trial targets non-Hodgkin lymphoma and tests the therapy both standalone and with rituximab, leveraging CAR-NK technology to address gaps in existing treatments. The company aims to generate critical data by the second half of 2025, potentially reshaping cancer treatment, with EF Hutton's $30 price target signaling a 357% gain.

ImmunityBio initiates Phase I trial of CD19-targeted high-affinity natural killer (t-haNK) cell therapy for non-Hodgkin’s lymphoma (NHL) in South Africa, aiming to enroll up to ten participants across Pretoria, Johannesburg, and Bloemfontein. The trial, QUILT 106, will assess safety and efficacy, potentially combining t-haNK cells with rituximab. Full enrollment expected by Q1 2025, with topline data anticipated in the latter half of 2025.

ImmunityBio initiates first CAR-NK (CD19 t-haNK) cellular therapy trial in Africa for non-Hodgkin's lymphoma, with full enrollment expected in Q1 2025.